• Abzena and OBI Pharma sign licence deal for ThioBridge technology pharmaceutical-technology
    July 13, 2017
    UK-based life sciences group Abzena has signed a licensing contract and a master service and clinical supply agreement with Taiwan, Chinaese biopharmaceutical company OBI Pharma to enable process development and manufacturing using ThioBridge.
PharmaSources Customer Service